Business

mass. movers

Agenus finalizes European acquisition

Associated Press/File 2010

Advertisement

Lexington-based Agenus Inc., which is developing novel immunotherapeutics, including anti-cancer vaccines, completed its acquisition of 4-Antibody AG, a private European biopharmaceutical company. Agenus acquired all outstanding stock of 4-Antibody for about 3.3 million shares of Agenus common stock, plus additional contingent payments that may exceed $40 million based on the combined company achieving certain milestones. Agenus intends to continue 4-Antibody’s operations in Basel, Switzerland, and Jena, Germany.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com